Genetic variation in antigen presentation and cancer immunotherapy

Human leukocyte antigen (HLA) molecules are critical mediators of anti-tumor immune responses. In this issue of Immunity, Chhibber et al. (2021) challenge previous associations between germline HLA zygosity and immunotherapy outcomes, demonstrating that germline HLA genotypes and diversity alone are not independent biomarkers of anti-PD1 clinical efficacy.

Automated summary

The study challenges previous associations between germline HLA genotypes and immunotherapy outcomes, indicating that germline HLA genotypes and diversity alone are not independent biomarkers of anti-PD1 clinical efficacy.